Karyopharm's SENTRY Trial to Present Groundbreaking Results at ASCO 2026 Meeting
Karyopharm Therapeutics Inc. is set to make waves in the oncology community with the late-breaking oral presentation of its Phase 3 SENTRY trial results at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled from May 29 to June 2 in Chicago. This pivotal trial evaluates the efficacy of combining selinexor with ruxolitinib in the treatment of myelofibrosis, a rare and challenging blood cancer.
The SENTRY trial's findings will be presented on June 2, 2026, at 9:45 a.m. Central Time by Dr. John Mascarenhas, a prominent figure in the field and the Director at the Center of Excellence for Blood Cancers and Myeloid Disorders at the Icahn School of Medicine. The abstract, titled "Selinexor plus ruxolitinib in JAK inhibitor–naïve myelofibrosis Phase 3 SENTRY trial," will be featured in the session dedicated to hematologic malignancies, including leukemia and myelodysplastic syndromes.
The significance of presenting a late-breaking abstract at ASCO underscores the potential impact Karyopharm’s research could have in altering treatment paradigms for patients with myelofibrosis. The SENTRY trial specifically investigates the use of selinexor, a first-in-class oral exportin 1 (XPO1) inhibitor, in a randomized and controlled setting to determine its effectiveness against the backdrop of ruxolitinib therapy, the current standard of care for myelofibrosis.
Conducted under the identifier NCT04562389, the SENTRY trial includes JAK inhibitor-naïve patients with myelofibrosis who are randomized into two groups: one receiving selinexor paired with ruxolitinib and another given placebo alongside ruxolitinib. The trial primarily aims to achieve two critical endpoints: a reduction in spleen volume by at least 35% after 24 weeks and an improvement in patient-reported symptom burden over the same period.
Approximately 20,000 people in the United States and 17,000 in the European Union are affected by myelofibrosis. The disease leads to severe complications, including bone marrow fibrosis, anemia, and splenomegaly, which disrupt normal blood cell production and severely diminish the quality of life for patients. Currently, ruxolitinib remains the only approved treatment for myelofibrosis, presenting a significant unmet medical need for additional effective therapies.
XPOVIO (selinexor) operates through a unique mechanism, inhibiting the export of tumor suppressor proteins from the nucleus of cancer cells, thereby promoting apoptosis or programmed cell death. Alongside ruxolitinib, this combination could potentially address the subset of patients who may not respond adequately to existing JAK inhibitors alone. Karyopharm’s innovative approach highlights its commitment to not only advancing cancer therapies but also addressing the urgent need for improved treatment outcomes in myelofibrosis.
As the clinical results of the SENTRY trial become available, the hope is that they will shed new light on treatment options, ultimately enhancing both survival rates and quality of life for myelofibrosis patients.
The presentation at ASCO will not only disseminate the trial results but will also involve the medical community in discussions that could shape future clinical practices. Following the conference, the findings will be made available on Karyopharm’s investor relations website, ensuring that the broader community can access and review the significant scientific contributions presented.
Karyopharm continues to pave the way in the field of oncology, driven by the belief in the potential of innovative therapies to change the landscape of cancer care. As Myelofibrosis remains a critical area requiring attention and new treatments, the upcoming ASCO meeting promises to be a pivotal moment in potentially revolutionizing standard practices for patients battling this devastating disease. Interested parties are encouraged to stay tuned to ASCO's release on June 2, 2026, when further details and a copy of the SENTRY presentation will become publicly accessible.
For ongoing updates and further information regarding clinical trials and Karyopharm’s pipeline, visit Karyopharm’s official website.
Presentation Details
The SENTRY trial's findings will be presented on June 2, 2026, at 9:45 a.m. Central Time by Dr. John Mascarenhas, a prominent figure in the field and the Director at the Center of Excellence for Blood Cancers and Myeloid Disorders at the Icahn School of Medicine. The abstract, titled "Selinexor plus ruxolitinib in JAK inhibitor–naïve myelofibrosis Phase 3 SENTRY trial," will be featured in the session dedicated to hematologic malignancies, including leukemia and myelodysplastic syndromes.
The significance of presenting a late-breaking abstract at ASCO underscores the potential impact Karyopharm’s research could have in altering treatment paradigms for patients with myelofibrosis. The SENTRY trial specifically investigates the use of selinexor, a first-in-class oral exportin 1 (XPO1) inhibitor, in a randomized and controlled setting to determine its effectiveness against the backdrop of ruxolitinib therapy, the current standard of care for myelofibrosis.
About the SENTRY Trial
Conducted under the identifier NCT04562389, the SENTRY trial includes JAK inhibitor-naïve patients with myelofibrosis who are randomized into two groups: one receiving selinexor paired with ruxolitinib and another given placebo alongside ruxolitinib. The trial primarily aims to achieve two critical endpoints: a reduction in spleen volume by at least 35% after 24 weeks and an improvement in patient-reported symptom burden over the same period.
Approximately 20,000 people in the United States and 17,000 in the European Union are affected by myelofibrosis. The disease leads to severe complications, including bone marrow fibrosis, anemia, and splenomegaly, which disrupt normal blood cell production and severely diminish the quality of life for patients. Currently, ruxolitinib remains the only approved treatment for myelofibrosis, presenting a significant unmet medical need for additional effective therapies.
The Role of XPOVIO
XPOVIO (selinexor) operates through a unique mechanism, inhibiting the export of tumor suppressor proteins from the nucleus of cancer cells, thereby promoting apoptosis or programmed cell death. Alongside ruxolitinib, this combination could potentially address the subset of patients who may not respond adequately to existing JAK inhibitors alone. Karyopharm’s innovative approach highlights its commitment to not only advancing cancer therapies but also addressing the urgent need for improved treatment outcomes in myelofibrosis.
As the clinical results of the SENTRY trial become available, the hope is that they will shed new light on treatment options, ultimately enhancing both survival rates and quality of life for myelofibrosis patients.
The presentation at ASCO will not only disseminate the trial results but will also involve the medical community in discussions that could shape future clinical practices. Following the conference, the findings will be made available on Karyopharm’s investor relations website, ensuring that the broader community can access and review the significant scientific contributions presented.
Looking Ahead
Karyopharm continues to pave the way in the field of oncology, driven by the belief in the potential of innovative therapies to change the landscape of cancer care. As Myelofibrosis remains a critical area requiring attention and new treatments, the upcoming ASCO meeting promises to be a pivotal moment in potentially revolutionizing standard practices for patients battling this devastating disease. Interested parties are encouraged to stay tuned to ASCO's release on June 2, 2026, when further details and a copy of the SENTRY presentation will become publicly accessible.
For ongoing updates and further information regarding clinical trials and Karyopharm’s pipeline, visit Karyopharm’s official website.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.